The main cause of death related to cancer worldwide is from hepatic cancer. Detection of hepatic cancer early using computed tomography (CT) could prevent millions of patients' death every year. However, reading hundreds or even tens of those CT scans is an enormous burden for radiologists. Therefore, there is an immediate need is to read, detect, and evaluate CT scans automatically, quickly, and accurately. However, liver segmentation and extraction from the CT scans is a bottleneck for any system, and is still a challenging problem. In this work, a deep learning-based technique that was proposed for semantic pixel-wise classification of road scenes is adopted and modified to fit liver CT segmentation and classification. The architecture of the deep convolutional encoder-decoder is named SegNet, and consists of a hierarchical correspondence of encode-decoder layers. The proposed architecture was tested on a standard dataset for liver CT scans and achieved tumor accuracy of up to 99.9% in the training phase.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085510 | PMC |
http://dx.doi.org/10.3390/s20051516 | DOI Listing |
Nat Commun
December 2024
Laboratory of Cellular Biophysics, The Rockefeller University, New York, NY, USA.
Fibrolamellar Hepatocellular Carcinoma (FLC) is a rare liver cancer characterized by a fusion oncokinase of the genes DNAJB1 and PRKACA, the catalytic subunit of protein kinase A (PKA). A few FLC-like tumors have been reported showing other alterations involving PKA. To better understand FLC pathogenesis and the relationships among FLC, FLC-like, and other liver tumors, we performed a massive multi-omics analysis.
View Article and Find Full Text PDFFront Immunol
December 2024
Medical Oncology, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France.
Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by enhancing the antitumor immune response. This case describes an 80-year-old male with synchronous multiple primary malignancies (MPMs), including lung metastatic hepatocellular carcinoma (HCC), and non-small cell lung carcinoma (NSCLC), and brain metastatic urothelial carcinoma, who was treated with dual ICI therapy.
Case Presentation: The patient, with a history of diabetes, hypertension, dyslipidaemia, well-differentiated neuroendocrine duodenal tumors and micronodular exogenous cirrhosis (Child-Pugh class A), presented with a non-invasive bladder carcinoma (pT1N0M0) resected endoscopically in December 2022.
BMC Med
December 2024
Department of Epidemiology & Biostatistics, School of Public Health, Peking University, 38 Xueyuan Road, Beijing, 100191, China.
Background: Risk prediction models can identify individuals at high risk of chronic liver disease (CLD), but there is limited evidence on the performance of various models in diverse populations. We aimed to systematically review CLD prediction models, meta-analyze their performance, and externally validate them in 0.5 million Chinese adults in the China Kadoorie Biobank (CKB).
View Article and Find Full Text PDFBMC Vet Res
December 2024
School of Statistics and Planning, Makerere University, Kampala, Uganda.
Background: In developing countries such as Uganda, domestic dogs suffer high burdens of infectious diseases often with high mortalities. Surveillance data on the common diseases and associated mortalities is however scanty. We thus, present results of a retrospective study of common clinical conditions and mortalities of dogs brought for treatment at the small animal clinic, Makerere University, Kampala, Uganda.
View Article and Find Full Text PDFBMC Womens Health
December 2024
The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, 315000, China.
Background: This study aimed to construct, evaluate, and validate nomograms for breast cancer-specific survival (BCSS) and overall survival (OS) prediction in patients with HER2- overexpressing (HER2+) metastatic breast cancer (MBC).
Methods: The Surveillance, Epidemiology, and End Results (SEER) database was used to select female patients diagnosed with HER2 + MBC between 2010 and 2015. These patients were distributed into training and validation groups (7:3 ratio).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!